A cocktail approach for assessing the in vitro activity of human cytochrome P450s: An overview of current methodologies

Journal of Pharmaceutical and Biomedical Analysis

Volumn 101, Issue , 2014, Pages 221-237

  Spaggiari, Dany ^a   Geiser, Laurent ^a   Daali, Youssef ^a   Rudaz, Serge ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cocktail; CYP phenotyping; Drug drug interactions; Human liver microsomes; In vitro methodology

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; ORGANIC SOLVENT;

ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SPECIFICITY; HUMAN; IN VITRO STUDY; INCUBATION TIME; METABOLIC ACTIVITY ASSAY; REVIEW; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 84908350475     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.03.018     Document Type: Review

References (177)

1. Testa B., Pedretti A., Vistoli G. Foundation review: reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discovery Today 2012, 17:549-560.
2. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360:1155-1162.
3. Rendic S., Guengerich F.P. Contributions of human enzymes in carcinogen metabolism. Chem. Res. Toxicol. 2012, 25:1316-1383.
4. Zhou S.F., Liu J.P., Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 2009, 41:89-295.
5. Samer C.F., Lorenzini K.I., Rollason V., Daali Y., Desmeules J.A. Applications of CYP450 testing in the clinical setting. Mol. Diagn. Ther. 2013, 17:165-184.
6. Lin J.H., Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 1998, 35:361-390.
7. Youdim K.A., Saunders K.C. A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s. J. Chromatogr. B 2010, 878:1326-1336.
8. Breimer D.D., Schellens J.H.M. A cocktail strategy to assess in vivo oxidative drug-metabolism in humans. Trends Pharmacol. Sci. 1990, 11:223-225.
9. Jerdi M.C., Daali Y., Oestreicher M.K., Cherkaoui S., Dayer P. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J. Pharmaceut. Biomed. 2004, 35:1203-1212.
10. Bosilkovska M., Déglon J., Samer C., Walder B., Desmeules J., Staub C., Daali Y. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis 2014, 6:151-164.
11. Tanaka E., Kurata N., Yasuhara H. How useful is the 'cocktail approach' for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?. J. Clin. Pharm. Ther. 2003, 28:157-165.
12. Zhou H.H., Tong Z., McLeod J.F. Cocktail approaches and strategies in drug development: valuable tool or flawed science?. J. Clin. Pharmacol. 2004, 44:120-134.
13. Fuhr U., Jetter A., Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the cocktail approach. Clin. Pharmacol. Ther. 2007, 81:270-283.
14. Frye R.E. Probing the world of cytochrone P450 enzymes. Mol. Interventions 2004, 4:157-162.
15. Yuan R., Madani S., Wei X.X., Reynolds K., Huang S.M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 2002, 30:1311-1319.
16. Donato M.T., Castell J.V. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism - focus on in vitro studies. Clin. Pharmacokinet. 2003, 42:153-178.
17. Guengerich F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21:70-83.
18. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 2001, 41:1149-1179.
19. Rolsted K., Kissmeyer A.M., Rist G.M., Hansen S.H. Evaluation of cytochrome P450 activity in vitro, using dermal and hepatic microsomes from four species and two keratinocyte cell lines in culture. Arch. Dermatol. Res. 2008, 300:10-18.
20. Mohutsky M.A., Petullo D.M., Wrighton S.A. The use of a substrate cassette strategy to improve the capacity and throughput of cytochrome P450 induction studies in human hepatocytes. Drug Metab. Dispos. 2005, 33:920-923.
21. Kanebratt K.P., Andersson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 2008, 36:1444-1452.
22. Tolosa L., Donato M.T., Perez-Cataldo G., Castell J.V., Gomez-Lechon M.J. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment. Toxicol. In Vitro 2012, 26:1272-1277.
23. Amunom I., Brawner S., Simpson J., Sawi J., Campbell R., Neat J., Parkinson A. In situ evaluation of CYP1A2, CYP2B6 and CYP3A4/5 induction in human hepatocytes with a cocktail of probe substrates. Drug Metab. Rev. 2009, 41:89.
24. Lyon K., Amunom I., Neat J.N., Holsapple J., Buckley D., Parkinson A. In situ evaluation of CYP1A2, CYP2B6 and CYP3A4/5 induction in cultured human hepatocytes with a cocktail of probe substrates: a comparison of percent positive control values. Drug Metab. Rev. 2010, 42:134-135.
25. Rhodes S.P., Otten J.N., Hingorani G.P., Hartley D.P., Franklin R.B. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2, J. Pharmacol. Toxicol. 2011, 63:223-226.
26. Halladay J.S., Wong S., Khojasteh S.C., Grepper S. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes. J. Pharmacol. Toxicol. 2012, 66:270-275.
27. Kim M.J., Kim H., Cha I.J., Park J.S., Shon J.H., Liu K.H., Shin J.G. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:2651-2658.
28. Kim H., Kang S., Kim H., Yoon Y.J., Cha E.Y., Lee H.S., Kim J.H., Yea S.S., Lee S.S., Shin J.G., Liu K.H. In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. Rapid Commun. Mass Spectrom. 2006, 20:837-843.
29. Kim H., Yoon Y.J., Kim H., Kang S., Cheon H.G., Yoo S.E., Shin J.G., Liu K.H. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. Toxicol. Lett. 2006, 166:105-114.
30. Kim K.B., Seo K.A., Yoon Y.J., Bae M.A., Cheon H.G., Shin J.G., Liu K.H. In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s. Xenobiotica 2008, 38:1165-1176.
31. Ahn H.J., Kim K.B., Liu K.H., Shin J.G., Ahn J.H., Kim M.S., Bae M.A., Song I.S. In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223. Xenobiotica 2011, 41:445-455.
32. Lee M., Park J., Lim M.S., Seong S.J., Lee J., Seo J.J., Park Y.K., Lee H.W., Yoon Y.R. High-throughput screening of inhibitory effects of Bo-yang-hwan-o-tang on human cytochrome P450 isoforms in vitro using UPLC/MS/MS. Anal. Sci. 2012, 28:1197-1201.
33. O'Donnell C.J., Grime K., Courtney P., Slee D., Riley R.J. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. Drug Metab. Dispos. 2007, 35:381-385.
34. Xing J., Kirby B.J., Whittington D., Wan Y.K., Goodlett D.R. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Drug Metab. Dispos. 2012, 40:1757-1764.
35. Wu X., Wang J., Tan L., Bui J., Gjerstad E., McMillan K., Zhang W. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome P450 inhibition and metabolic stability assays. J. Biomol. Screen. 2012, 17:761-772.
36. Di L., Kerns E.H., Li S.Q., Carter G.T. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int. J. Pharm. 2007, 335:1-11.
37. Mori K., Hashimoto H., Takatsu H., Tsuda-Tsukimoto M., Kume T. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 2009, 39:415-422.
38. Dixit V., Hariparsad N., Desai P., Unadkat J.D. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm. Drug Dispos. 2007, 28:257-262.
39. Bu H.Z., Knuth K., Magis L., Teitelbaum P. High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Commun. Mass Spectrom. 2000, 14:1943-1948.
40. Kenny J.R., Chen L., McGinnity D.F., Grime K., Shakesheff K.M., Thomson B., Riley R. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 2008, 38:1500-1517.
41. Darnell M., Schreiter T., Zeilinger K., Urbaniak T., Soderdahl T., Rossberg I., Dillner B., Berg A.L., Gerlach J.C., Andersson T.B. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab. Dispos. 2011, 39:1131-1138.
42. Mueller D., Tascher G., Muller-Vieira U., Knobeloch D., Nuessler A.K., Zeilinger K., Heinzle E., Noor F. In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J. Tissue Eng. Regen. Med. 2011, 5:E207-E218.
43. Gerin B., Dell'Aiera S., Boekens H., Smith S., Chanteux H. Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy. Drug Metab. Rev. 2010, 42:132.
44. Alexandre E., Baze A., Parmentier C., Desbans C., Pekthong D., Gerin B., Wack C., Bachellier P., Heyd B., Weber J.C., Richert L. Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers. Xenobiotica 2012, 42:968-979.
45. Pelletier R.D., Lai W.G., Wong Y.N. Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes. J. Biomol. Screen. 2013, 18:199-210.
46. Liu L., Mugundu G.M., Kirby B.J., Samineni D., Desai P.B., Unadkat J.D. Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. Biopharm. Drug Dispos. 2012, 33:207-217.
47. Lee K.S., Kim S.K. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. J. Appl. Toxicol. 2013, 33:100-108.
48. Lee S.Y., Lee J.Y., Kang W., Kwon K.I., Oh S.J., Ma J.Y., Kim S.K. In vitro and in vivo assessment of cytochrome P450-mediated herb-drug interaction of Ssang-hwa-tang. Food Chem. 2013, 136:450-457.
49. Lahoz A., Donata M.T., Montero S., Castell J.V., Gomez-Lechon M.J. A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations. Rapid Commun. Mass Spectrom. 2008, 22:240-244.
50. Alden P.G., Plumb R.S., Jones M.D., Rainville P.D., Shave D. A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of pooled and cocktail cytochrome P450 assays. Rapid Commun. Mass Spectrom. 2010, 24:147-154.
51. Weaver R., Graham K.S., Beattie I.G., Riley R.J. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. 2003, 31:955-966.
52. Atkinson A., Kenny J.R., Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos. 2005, 33:1637-1647.
53. McGinnity D.F., Berry A.J., Kenny J.R., Grime K., Riley R.J. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos. 2006, 34:1291-1300.
54. Pillai V.C., Strom S.C., Caritis S.N., Venkataramanan R. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. J. Pharm. Biomed. Anal. 2013, 74:126-132.
55. Floby E., Briem S., Terelius Y., Sohlenius-Sternbeck A.K. Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations. Xenobiotica 2004, 34:949-959.
56. Floby E., Johansson J., Hoogstraate J., Hewitt N.J., Hill J., Sohlenius-Sternbeck A.K. Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 2009, 39:656-662.
57. Testino S.A., Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J. Pharmaceut. Biomed. 2003, 30:1459-1467.
58. Ren S., Zeng J., Mei Y., Zhang J.Z.H., Yan S.F., Fei J., Chen L. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab. Dispos. 2013, 41:60-71.
59. Youdim K.A., Tyman C.A., Jones B.C., Hyland R. Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. Drug Metab. Dispos. 2007, 35:275-282.
60. Smith D., Sadagopan N., Zientek M., Reddy A., Cohen L. Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J. Chromatogr. B 2007, 850:455-463.
61. Zientek M., Miller H., Smith D., Dunklee M.B., Heinle L., Thurston A., Lee C., Hyland R., Fahmi O., Burdette D. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J. Pharmacol. Toxicol. Methods 2008, 58:206-214.
62. Youdim K.A., Lyons R., Payne L., Jones B.C., Saunders K. An automated, high-throughput, 384 well cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. J. Pharmaceut. Biomed. 2008, 48:92-99.
63. Nath A., Zientek M.A., Burke B.J., Jiang Y., Atkins W.M. Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors. Drug Metab. Dispos. 2010, 38:2195-2203.
64. Bu H.Z., Magis L., Knuth K., Teitelbaum P. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun. Mass Spectrom. 2001, 15:741-748.
65. Prot J.M., Videau O., Brochot C., Legallais C., Benech H., Leclerc E. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int. J. Pharm. 2011, 408:67-75.
66. Baudoin R., Prot J.M., Nicolas G., Brocheton J., Brochot C., Legallais C., Benech H., Leclerc E. Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 2013, 43:140-152.
67. Lahoz A., Donato M.T., Picazo L., Castell J.V., Gomez-Lechon M.J. Assessment of cytochrome P450 induction in human hepatocytes using the cocktail strategy plus liquid chromatography tandem mass spectrometry. Drug Metab. Lett. 2008, 2:205-209.
68. Im Y., Kim Y.W., Song I.S., Joo J., Shin J.H., Wu Z.X., Lee H.S., Park K.H., Liu K.H. Effect of TSHAC on human cytochrome P450 activity, and transport mediated by P-glycoprotein. J. Microbiol. Biotechnol. 2012, 22:1659-1664.
69. Rainville P.D., Wheaton J.P., Alden P.G., Plumb R.S. Sub one minute inhibition assays for the major cytochrome P450 enzymes utilizing ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:1345-1350.
70. Lee C.A., Jones J.P., Katayama J., Kaspera R., Jiang Y., Freiwald S., Smith E., Walker G.S., Totah R.A. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab. Dispos. 2012, 40:943-951.
71. Zhang T.Y., Zhu Y.X., Gunaratna C. Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry. J. Chromatogr. B 2002, 780:371-379.
72. He F., Bi H.C., Xie Z.Y., Zuo Z., Li J.K., Li X., Zhao L.Z., Chen X., Huang M. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun. Mass Spectrom. 2007, 21:635-643.
73. Unger M., Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography mass spectrometry and automated online extraction. Rapid Commun. Mass Spectrom. 2004, 18:2273-2281.
74. Dierks E.A., Stams K.R., Lim H.K., Cornelius G., Zhang H.L., Ball S.E. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 2001, 29:23-29.
75. Bu H.Z., Magis L., Knuth K., Teitelbaum P. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites. Rapid Commun. Mass Spectrom. 2000, 14:1619-1624.
76. Moreno-Farre J., Workman P., Raynaud F. Analysis of potential drug-drug interactions for anticancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay. Aust. J. Cancer 2007, 6:55-69.
77. Ji H.Y., Kim S.Y., Kim D.K., Jeong J.H., Lee H.S. Effects of eupatilin and jaceosidin on cytochrome P450 enzyme activities in human liver microsomes. Molecules 2010, 15:6466-6475.
78. Ji H.Y., Liu K.H., Lee H., Im S.R., Shim H.J., Son M., Lee H.S. Corydaline inhibits multiple cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 2011, 16:6591-6602.
79. Ji H.Y., Liu K.H., Jeong J.H., Lee D.Y., Shim H.J., Son M., Lee H.S. Effect of a new prokinetic agent DA-9701 formulated with corydalis tuber and pharbitidis semen on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Evid. Based Complement Altern. 2012, 1-7.
80. Otten J.N., Hingorani G.P., Hartley D.P., Kragerud S.D., Franklin R.B. An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. Drug Metab. Lett. 2011, 5:17-24.
81. Feidt D.M., Klein K., Hofmann U., Riedmaier S., Knobeloch D., Thasler W.E., Weiss T.S., Schwab M., Zanger U.M. Profiling induction of cytochrome P450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab. Dispos. 2010, 38:1589-1597.
82. Han Y.L., Yu H.L., Li D., Meng X.L., Zhou Z.Y., Yu Q., Zhang X.Y., Wang F.J., Guo C. Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro. Toxicol. In Vitro 2011, 25:1828-1833.
83. Gomez-Lechon M.J., Lahoz A., Castell J.V., Donato M.T. Evaluation of cytochrome P450 activities in human hepatocytes in vitro. Methods Mol. Biol. 2012, 806:87-97.
84. Antherieu S., Chesne C., Li R.Y., Camus S., Lahoz A., Picazo L., Turpeinen M., Tolonen A., Uusitalo J., Guguen-Guillouzo C., Guillouzo A. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos. 2010, 38:516-525.
85. Kozakai K., Yamada Y., Oshikata M., Kawase T., Suzuki E., Haramaki Y., Taniguchi H. Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. Drug Metab. Pharmacokinet. 2012, 27:520-529.
86. Jahng Y., Kwon O.K., Lee S. In vitro inhibitory effect of luotonin A on human CYP1A. Arch. Pharm. Res. 2012, 35:2199-2203.
87. Kim H., Choi H.K., Jeong T.C., Jahng Y., Kim D.H., Lee S.H., Lee S. Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes. Food Chem. Toxicol. 2013, 51:33-37.
88. Turpeinen M., Jouko U., Jorma J., Olavi P. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 2005, 24:123-132.
89. Turpeinen M., Korhonen L.E., Tolonen A., Uusitalo J., Juuonen R., Raunio H., Pelkonen A. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur. J. Pharm. Sci. 2006, 29:130-138.
90. Korjamo T., Monkkonen J., Uusitalo J., Turpeinen M., Pelkonen O., Honkakoski P. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm. Res. 2006, 23:1991-2001.
91. Tolonen A., Petsalo A., Turpeinen M., Uusitalo J., Pelkonen O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J. Mass Spectrom. 2007, 42:960-966.
92. Korhonen T., Turpeinen M., Tolonen A., Laine K., Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. 2008, 110:56-66.
93. Abass K., Reponen P., Mattila S., Pelkonen O. Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem. Biol. Interact. 2010, 185:163-173.
94. Sevior D.K., Hokkanen J., Tolonen A., Abass K., Tursas L., Pelkonen O., Ahokas J.T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010, 40:245-254.
95. Hokkanen J., Tolonen A., Mattila S., Turpeinen M. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur. J. Pharm. Sci. 2011, 42:273-284.
96. Abass K., Reponen P., Mattila S., Pelkonen O. Metabolism of alpha-thujone in human hepatic preparations in vitro. Xenobiotica 2011, 41:101-111.
97. Abass K., Pelkonen O. The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches. Toxicol. In Vitro 2012, 27:1584-1588.
98. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
99. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31:815-832.
100. Walsky R.L., Obach R.S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 2004, 32:647-660.
101. Patki K.C., von Moltke L.L., Greenblatt D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos. 2003, 31:938-944.
102. Niwa T., Shiraga T., Yamasaki S., Ishibashi K., Ohno Y., Kagayama A. In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica 2003, 33:717-729.
103. Curipedrosa R., Daujat M., Pichard L., Ourlin J.C., Clair P., Gervot L., Lesca P., Domergue J., Joyeux H., Fourtanier G., Maurel P. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 1994, 269:384-392.
104. Kobayashi K., Nakajima M., Oshima K., Shimada N., Yokoi T., Chiba K. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab. Dispos. 1999, 27:860-865.
105. Draper A.J., Madan A., Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 1997, 341:47-61.
106. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996, 26:681-693.
107. Woolf T.F., Pool W.F., Bjorge S.M., Chang T., Goel O.P., Purchase C.F., Schroeder M.C., Kunze K.L., Trager W.F. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat-liver microsomal preparations - species difference. Drug Metab. Dispos. 1993, 21:874-882.
108. Spaldin V., Madden S., Pool W.F., Woolf T.F., Park B.K. The effect of enzyme-inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol. 1994, 38:15-22.
109. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., Mayer R.T. Cytochrome-P450 specifities of alkoxyresorufin O-dealkylation in human and rat-liver. Biochem. Pharmacol. 1994, 48:923-936.
110. Masimirembwa C.M., Otter C., Berg M., Jonsson M., Leidvik B., Jonsson E., Johansson T., Backman A., Edlund A., Andersson T.B. Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab. Dispos. 1999, 27:1117-1122.
111. Yeleswaram K., Vachharajani N., Santone K. Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications. J. Pineal Res. 1999, 26:190-191.
112. Hartter S., Wang X.M., Weigmann H., Friedberg T., Arand M., Oesch F., Hiemke C. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J. Clin. Psychopharm. 2001, 21:167-174.
113. Facciola G., Hidestrand M., von Bahr C., Tybring G. Cytochrome P-450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol. 2001, 56:881-888.
114. Ma X.C., Idle J.R., Krausz K.W., Gonzalez F.J. Metabolism of melatonin by human cytochromes P450. Drug Metab. Dispos. 2005, 33:489-494.
115. Faucette S.R., Hawke R.L., Lecluyse E.L., Shord S.S., Yan B.F., Laethem R.M., Lindley C.M. Validation of bupropion hydroxylation as a selective marker of human cytochrome P4502B6 catalytic activity. Drug Metab. Dispos. 2000, 28:1222-1230.
116. Faucette S.R., Hawke R.L., Shord S.S., Lecluyse E.L., Lindley C.M. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab. Dispos. 2001, 29:1123-1129.
117. Hesse L.M., Venkatakrishnan K., Court M.H., Von Moltke L.L., Duan S.X., Shader R.I., Greenblatt D.J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 2000, 28:1176-1183.
118. Rahman A., Korzekwa K.R., Grogan J., Gonzalez F.J., Harris J.W. Selective biotransformation of taxol to 6-alpha.hydroxytaxol by human cytochrome-P450 2C8. Cancer Res. 1994, 54:5543-5546.
119. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. Variability in human cytochrome-P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 1995, 275:566-575.
120. Desai P.B., Duan J.Z., Zhu Y.W., Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur. J. Drug Metab. Pharmacokinet. 1998, 23:417-424.
121. Wang Y., Unadkat J.D. Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm. Drug Dispos. 1999, 20:341-346.
122. Walsky R.L., Astuccio A.V., Obach R.S. Evaluation of 227 drugs for in vitro inhibition of cytochrome P4502B6. J. Clin. Pharmacol. 2006, 46:1426-1438.
123. Li X.Q., Bjorkman A., Andersson T.B., Ridderstrom M., Masimirembwa C.M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 2002, 300:399-407.
124. Bapiro T.E., Egnell A.C., Hasler J.A., Masimirembwa C.M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab. Dispos. 2001, 29:30-35.
125. Sall C., Houston J.B., Galetin A.A. Comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab. Dispos. 2012, 40:1279-1289.
126. Bidstrup T.B., Bjornsdottir I., Sidelmann U.G., Thomsen M.S., Hansen K.T. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br. J. Clin. Pharmacol. 2003, 56:305-314.
127. Kajosaari L.I., Laitila J., Neuvonen P.J., Backman J.T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. 2005, 97:249-256.
128. Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., Goldstein J.A., Guengerich F.P., Shimada T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of Warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol. 1998, 56:243-251.
129. Tang W., Stearns R.A., Wang R.W., Chiu S.H.L., Baillie T.A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 1999, 12:192-199.
130. Shen S.J., Marchick M.R., Davis M.R., Doss G.A., Pohl L.R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 1999, 12:214-222.
131. Leemann T., Transon C., Dayer P. Cytochrome P450TB (CYP2C) - a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci. 1993, 52:29-34.
132. Goldstein J.A., Faletto M.B., Romkessparks M., Sullivan T., Kitareewan S., Raucy J.L., Lasker J.M., Ghanayem B.I. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry-US 1994, 33:1743-1752.
133. Andersson T., Miners J.O., Veronese M.E., Tassaneeyakul W., Tassaneeyakul W., Meyer U.A., Birkett D.J. Identification of human liver cytochrome-P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 1993, 36:521-530.
134. Chiba K., Kobayashi K., Manabe K., Tani M., Kamataki T., Ishizaki T. Oxidative-metabolism of omeprazole in human liver microsomes - cosegregation with S-mephenytoin 4'-hydroxylation. J. Pharmacol. Exp. Ther. 1993, 266:52-59.
135. Abelo A., Andersson T.B., Antonsson M., Naudot A.K., Skanberg I., Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000, 28:966-972.
136. Karam W.G., Goldstein J.A., Lasker J.M., Ghanayem B.I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 1996, 24:1081-1087.
137. Ekpe A., Jacobsen T. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography. Drug Dev. Ind. Pharm. 1999, 25:1057-1065.
138. Li X.Q., Weidolf L., Simonsson R., Andersson T.B. Enantiomer/enantiomer interactions between the S- and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J. Pharmacol. Exp. Ther. 2005, 315:777-787.
139. Zvyaga T., Chang S.Y., Chen C., Yang Z., Vuppugalla R., Hurley J., Thorndike D., Wagner A., Chimalakonda A., Rodrigues A.D. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab. Dispos. 2012, 40:1698-1711.
140. Afzelius L., Zamora I., Ridderstrom M., Andersson T.B., Karlen A., Masimirembwa C.M. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 2001, 59:909-919.
141. Ono S., Hatanaka T., Miyazawa S., Tsutsui M., Aoyama T., Gonzalez F.J., Satoh T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996, 26:1155-1166.
142. Koyama E., Chiba K., Tani M., Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J. Pharmacol. Exp. Ther. 1997, 281:1199-1210.
143. Ghahramani P., Ellis S.W., Lennard M.S., Ramsay L.E., Tucker G.T. Cytochromes p450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 1997, 43:137-144.
144. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol. 1998, 38:112-121.
145. Niwa T., Shiraga T., Ishii I., Kagayama A., Takagi A. Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull. 2005, 28:1711-1716.
146. Kroemer H.K., Mikus G., Kronbach T., Meyer U.A., Eichelbaum M. In vitro characterization of the human cytochrome P450 involved in polymorphic oxidation of propafenone. Clin. Pharmacol. Ther. 1989, 45:28-33.
147. Botsch S., Gautier J.C., Beaune P., Eichelbaum M., Kroemer H.K. Identification and characterization of the cytochrome-P450 enzymes involved in N-dealkylation of propafenone - molecular-base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 1993, 43:120-126.
148. Kobayashi K., Nakajima M., Chiba K., Yamamoto T., Tani M., Ishizaki T., Kuroiwa Y. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br. J. Clin. Pharmacol. 1998, 45:361-368.
149. Chiba P., Ecker G., Schmid D., Drach J., Tell B., Goldenberg S., Gekeler V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 1996, 49:1122-1130.
150. Sevrioukova I.F., Poulos T.L. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans. 2013, 42:3116-3126.
151. Liu Y.T., Hao H.P., Liu C.X., Wang G.J., Xie H.G. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab. Rev. 2007, 39:699-721.
152. Thummel K.E., Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. 1998, 38:389-430.
153. Huang W.L., Lin Y.S., McConn D.J., Calamia J.C., Totah R.A., Isoherranen N., Glodowski M., Thummel K.E. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab. Dispos. 2004, 32:1434-1445.
154. Ekroos M., Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13682-13687.
155. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 2000, 32:339-361.
156. Kenworthy K.E., Bloomer J.C., Clarke S.E., Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 1999, 48:716-727.
157. Galetin A., Ito K., Hallifax D., Houston J.B. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J. Pharmacol. Exp. Ther. 2005, 314:180-190.
158. Watanabe A., Nakamura K., Okudaira N., Okazaki O., Sudo K.I. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab. Dispos. 2007, 35:1232-1238.
159. Hamaoka N., Oda Y., Hase I., Asada A., Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. Br. J. Anaesth. 2001, 86:540-544.
160. Guengerich F.P., Martin M.V., Beaune P.H., Kremers P., Wolff T., Waxman D.J. Characterization of rat and human-liver microsomal cytochrome-P450 forms involved in nifedipine oxidation, a prototype for genetic-polymorphism in oxidative drug-metabolism. J. Biol. Chem. 1986, 261:5051-5060.
161. Guengerich F.P., Brian W.R., Iwasaki M., Sari M.A., Baarnhielm C., Berntsson P. Oxidation of dihydropyridine calcium-channel blockers and analogs by human liver cytochrome-P450 IIIA4. J. Med. Chem. 1991, 34:1838-1844.
162. Yamazaki H., Nakano M., Imai Y., Ueng Y.F., Guengerich F.P., Shimada T. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 1996, 325:174-182.
163. Jacqzaigrain E., Funckbrentano C., Cresteil T. CYP2D6-dependent and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993, 3:197-204.
164. Gorski J.C., Jones D.R., Wrighton S.A., Hall S.D. Characterization of dextromethorphan N-demethylation by human liver-microsomes - contribution of the cytochrome-P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 1994, 48:173-182.
165. Schmider J., Greenblatt D.J., Fogelman S.M., VonMoltke L.L., Shader R.I. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm. Drug Dispos. 1997, 18:227-240.
166. Yu A.M., Dong H.J., Lang D., Haining R.L. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab. Dispos. 2001, 29:1362-1365.
167. Yu A.M., Haining R.L. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?. Drug Metab. Dispos. 2001, 29:1514-1520.
168. Chauret N., Gauthier A., Nicoll-Griffith D.A. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 1998, 26:1-4.
169. Hickman D., Wang J.P., Wang Y., Unadkat J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos. 1998, 26:207-215.
170. Busby W.F., Ackermann J.M., Crespi C.L. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab. Dispos. 1999, 27:246-249.
171. Easterbrook J., Lu C., Sakai Y., Li A.P. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab. Dispos. 2001, 29:141-144.
172. Mazur C.S., Kenneke J.F., Goldsmith M.R., Brown C. Contrasting Influence of NADPH and a NADPH-Regenerating System on the Metabolism of Carbonyl-Containing Compounds in Hepatic Microsomes. Drug Metab. Dispos. 2009, 37:1801-1805.
173. Venkatakrishnan K., Von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 2000, 28:1493-1504.
174. Tucker G.T., Houston J.B., Huang S.M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br. J. Clin. Pharmacol. 2001, 52:107-117.
175. Souverain S., Rudaz S., Veuthey J.L. Protein precipitation for the analysis of a drug cocktail in plasma by LC-ESI-MS. J. Pharmaceut. Biomed. 2004, 35:913-920.
176. Souverain S., Rudaz S., Veuthey J.L. Matrix effect in LC-ESI-MS and LC-APCI-MS with off-line and on-line extraction procedures. J. Chromatogr. A 2004, 1058:61-66.
177. Ma B., Subramanian R., Schrag M.L., Rodrigues A.D., Tang C.Y. Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes. Drug Metab. Dispos. 2004, 32:473-478.